CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

Leukemia

Volumn 29, Issue 5, 2015, Pages 1209-1210

  Finazzi, M C ^a   Carobbio, A ^a   Cervantes, F ^b   Isola, I M ^b   Vannucchi, A M ^c   Guglielmelli, P ^c   Rambaldi, A ^a   Finazzi, G ^a   Barosi, G ^d   Barbui, T ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF FLORENCE   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

GENE MUTATION; HUMAN; LETTER; MEDICAL RECORD REVIEW; MYELOFIBROSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; CLINICAL TRIAL; COMPLICATION; EUROPE; FOLLOW UP; GENETICS; INCIDENCE; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA; TREATMENT OUTCOME;

CALRETICULIN; DNA MUTATIONAL ANALYSIS; EUROPE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JANUS KINASE 2; MUTATION; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; TREATMENT OUTCOME;

EID: 84929295666     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.343     Document Type: Letter

References (6)

1. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115: 778-782.
2. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defi nes subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544-1551.
3. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552-1555.
4. Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 2014; 124: 2611-2612.
5. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124: 2507-2513.
6. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014; 124: 1062-1069.